



(51) International Patent Classification:

C07D 471/04 (2006.01) *A61K 31/52* (2006.01)
C07D 487/04 (2006.01) *A61P 9/00* (2006.01)
A61K 31/437 (2006.01) *A61P 19/02* (2006.01)

(21) International Application Number:

PCT/EP2014/054770

(22) International Filing Date:

12 March 2014 (12.03.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

13305283.7 13 March 2013 (13.03.2013) EP

(71) Applicant: SANOFI [FR/FR]; 54 rue La Boétie, F-75008 Paris (FR).

(72) Inventors: **NAZARÉ, Marc**; c/o Sanofi-Aventis Deutschland GmbH, Industriepark Hoechst, 65926 Frankfurt am Main (DE). **HALLAND, Nis**; c/o Sanofi-Aventis Deutschland GmbH, Industriepark Hoechst, 65926 Frankfurt am Main (DE). **SCHMIDT, Friedemann**; c/o Sanofi-Aventis Deutschland GmbH, Industriepark Hoechst, 65926 Frankfurt am Main (DE). **KLEEMANN, Heinz-Werner**; c/o Sanofi-Aventis Deutschland GmbH, Industriepark Hoechst, 65926 Frankfurt am Main (DE). **WEISS, Tilo**; c/o Sanofi-Aventis Deutschland GmbH, Industriepark Hoechst, 65926 Frankfurt am Main (DE). **SAAS, Joachim**; c/o Sanofi-Aventis Deutschland GmbH, Industriepark Hoechst, 65926 Frankfurt am Main (DE). **STRUEBING, Carsten**; c/o Sanofi-Aventis Deutschland GmbH, Industriepark Hoechst, 65926 Frankfurt am Main (DE).

(74) Agent: **KUJATH, Eckard**; c/o Sanofi-Aventis Deutschland GmbH, Global Intellectual Property Department, Industriepark Hoechst, Geb. K 703, 65926 Frankfurt am Main (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS



(57) Abstract: N-(4-(Azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals The present invention relates to N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides of the formula I, wherein Ar, n, X, Z, R1, R2 and R3 have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

